Page 108 - sjsi

Research Article: Aljamali & Youssef 108

23 . Alshahawey M et al. Sex-mediated effects of ACE2 11 . NIH Medline Plus bulletin.
and TMPRSS2 on the incidence and severity of https://medlineplus.gov/genetics/understanding/

COVID-19; the need for genetic implementation. genomicresearch/snp / .
Current Research in Translational Medicine (2020); 12 . Dieter C, Brondani L, Lemos NE, et al. Polymorphisms
68:149–150 . in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2. Genes
24 . Rokni M, Heidari M, Nia MH, et al. Association of Are Associated with Worse Clinical Outcomes in
TMPRSS2 Gene Polymorphisms with COVID‑19 COVID-19. Genes (2023), 14, 29.
Severity and Mortality: a Case‑Control Study with https://doi.org/10.3390/ genes14010029 .
Computational Analyses. Applied Biochemistry and 13 . Asselta R, Paraboschi EM, Mantovani A, Duga S.
Biotechnology, (2022) 194:3507–3526. ACE2 and TMPRSS2 variants and expression as
https://doi.org/10.1007/s12010-022-03885-w . candidates to sex and country differences in COVID-
25 . Wettstein L, Immenschuh P, Weil T, et al. Native and 19 severity in Italy. Aging (2020); 12:10087-98 .
activated antithrombin inhibitsTMPRSS2 activity and 14 . Yildirim Z, Sahin OS, Yazar S, and Cetintas VB. (2021)
SARS‐CoV‐2 infection. J Med Virol. (2022); 95: Genetic and epigenetic factors associated with
e28124 . increased severity of Covid‐19. Cell Biology
26 . Wettstein L, Kirchhoff F, Munch J. The International, Cell Biol Int. (2021); 45:1158–1174.
Transmembrane Protease TMPRSS2 as a Therapeutic DOI: 10.1002/cbin.11572 .
Target for COVID-19 Treatment. Int. J. Mol. Sci. 15 . Wulandari L, Hamidah B, Pakpahan C, et al. (2021)
(2022), 23, 1351. Initial study on TMPRSS2 p.Val160Met genetic
https://doi.org/10.3390/ijms23031351 . variant in COVID-19 patients. Human Genomics
(2021) 15:29. doi.org/10.1186/s40246-021-00330-7 .

16 . Shirazi SSB, Sakhaee F, Sotoodehnejadnematalahi F,
نافرعلاو ركشلا et al. rs12329760 Polymorphism in Transmembrane
Serine Protease 2 Gene and Risk of Coronavirus
زيمتملا ينقتلا معدلا ىلع يكاطن أ ماهر ةسنلآل ليزجلا ركشلاب ناثحابلا مدقتي
Disease 2019 Mortality. BioMed Research
ةيويحلا تاناقتلا مسق يف نيلماعلا رئاسلو ،لمعلا زاجنلإ هتمدق يذلا International (2022).
.ةيويحلا ةناقتلل ةماعلا ةئيهلا يف ةيعانملاو ةينلاديصلا doi.org/10.1155/2022/7841969 .
17 . Monticelli M, Mele BH, Benetti E, et al. Protective
Role of a TMPRSS2 Variant on Severe COVID-19
Outcome in Young Males and Elderly Women. Genes
(2021), 12, 596. https://doi.org/
10.3390/genes12040596 .
18 . Saengsiwaritt W, Jittikoon J, Chaikledkaew U, and
Udomsinprasert W. Genetic polymorphisms of ACE1,
ACE2, and TMPRSS2 associated with COVID‐19
severity: A systematic review with meta‐analysis.
Rev Med Virol. (2022); 32:e2323.
https://doi.org/10.1002/rmv.2323 .
19 . Ravikanth V., Sasikala M., Naveen V., et al. A variant
in TMPRSS2 is associated with decreased disease
severity in COVID-19. Meta Gene (2021), 29, 100930 .
20 . Abdelsattar S, Kasemy ZA, Ewida SF, et al. ACE2 and
TMPRSS2 SNPs as determinants of susceptibility to,
and severity of, a covid-19 infection. Br J Biomed Sci
(2022), 79:10238. doi: 10.3389/bjbs.2021.10238
21 . Duman N. Tuncel G, Bisgin A, et al. Analysis of ACE2
and TMPRSS2 coding variants as a risk factor for
SARS-CoV-2 from 946 whole exome sequencing data
in the Turkish Population. J Med Vir. (2022). doi:
10.1002/jmv.27976
22 . Shibata S, Kobayashi K, Tanaka M, et al. COVID-19
pandemic and hypertension: an updated report from
the Japanese Society of Hypertension project team
on COVID-19. Hypertension Research (2023) 46:589–
600. https://doi.org/10.1038/s41440-022-01134-5 .

SJSI – 2023: VOLUME 1-1